Karpiuk Izabela, Tyski Stefan
Zakład Antybiotyków i Mikrobiologii, Narodowy Instytut Leków, Warszawa.
Przegl Epidemiol. 2012;66(4):567-73.
Development of new mechanisms of resistance and relatively easy and fast transferring of resistance genes between cells have resulted in emergence of large number of multi-drug resistant bacteria in recent years. Therefore, it is important to intensively search for new, effective compounds possessing antibacterial potential and apply them as active ingredients of medicinal products. This procedure may lead to eradication of clinically relevant, dangerous bacteria. In the twentyfirst century, three new classes of antibacterial agents: oxazolidinones, lipopeptides and pleuromutilins were introduced into the therapy. Compounds from the last group, such as tiamulin, were used previously, but only in veterinary. New 18 antimicrobial compounds, belonging to known therapeutic groups, have been registered since 2000. The largest group among antibacterial chemotherapeutics is quinolones. Group of natural compounds includes: new carbapenems, cephalosporins of V generation and other agents, like telithromycin, tigecycline, telavancin and fidaxomicin. This article is a part of the series associated with searching for new antibacterial agents and it relates to new antibiotics and antibacterial chemotherapeutics approved for the world-wide market since 2000. The next parts of this cycle will be devoted to compounds ongoing the clinical trials.
近年来，耐药新机制的出现以及耐药基因在细胞间相对容易且快速的转移导致了大量多重耐药细菌的出现。因此，大力寻找具有抗菌潜力的新型有效化合物并将其用作药品的活性成分至关重要。这一过程可能会根除临床上相关的危险细菌。在21世纪，三类新型抗菌剂：恶唑烷酮类、脂肽类和截短侧耳素类被引入治疗。最后一组中的化合物，如泰妙菌素，以前仅用于兽医领域。自2000年以来，已有18种属于已知治疗类别的新型抗菌化合物注册。抗菌化疗药物中最大的一类是喹诺酮类。天然化合物组包括：新型碳青霉烯类、第五代头孢菌素以及其他药物，如泰利霉素、替加环素、达托霉素和非达霉素。本文是寻找新型抗菌剂系列文章的一部分，涉及自2000年以来在全球市场获批的新型抗生素和抗菌化疗药物。本系列的后续部分将致力于正在进行临床试验的化合物。
